Based on these new classifications, a multicenter, retrospective study including 220 patients with DLBCL revealed that MYC/BCL6 patients had superior and longer OS than patients with MYC/BCL2-rearrangements and THL, and treatment intensification was associated with next treatment time and OS in patients with MYC/BCL2 and THL but no improvement in MYC/BCL6 patients [41]. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.